Economic impact of medication non-adherence by disease groups: a systematic review
Open accessThe DOI matches its Crossref record; 98 of the 113 references it cites were found in a registry or an index; 5 of the 59 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To determine the economic impact of medication non-adherence across multiple disease groups. DESIGN: Systematic review. EVIDENCE REVIEW: A comprehensive literature search was conducted in PubMed and Scopus in September 2017. Studies quantifying the cost of medication non-adherence in relation to economic impact were included. Relevant information was extracted and quality assessed using the Drummond checklist. RESULTS: Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included. Wide-scoping cost variations were reported, with lower levels of adherence generally associated with higher total costs. The annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44 190 (in 2015 US$). Costs attributed to 'all causes' non-adherence ranged from $5271 to $52 341. Medication possession ratio was the metric most used to calculate patient adherence, with varying cut-off points defining non-adherence. The main indicators used to measure the cost of non-adherence were total cost or total healthcare cost (83% of studies), pharmacy costs (70%), inpatient costs (46%), outpatient costs (50%), emergency department visit costs (27%), medical costs (29%) and hospitalisation costs (18%). Drummond quality assessment yielded 10 studies of high quality with all studies performing partial economic evaluations to varying extents. CONCLUSION: Medication non-adherence places a significant cost burden on healthcare systems. Current research assessing the economic impact of medication non-adherence is limited and of varying quality, failing to provide adaptable data to influence health policy. The correlation between increased non-adherence and higher disease prevalence should be used to inform policymakers to help circumvent avoidable costs to the healthcare system. Differences in methods make the comparison among studies challenging and an accurate estimation of true magnitude of the cost impossible. Standardisation of the metric measures used to estimate medication non-adherence and development of a streamlined approach to quantify costs is required. PROSPERO REGISTRATION NUMBER: CRD42015027338.
Overview
CoChat Summary
## TL;DR
This systematic review found that medication non-adherence is generally associated with higher healthcare costs across 14 disease groups, but the reported costs varied widely and could not be meaningfully pooled because of heterogeneity. Across 79 included studies, the adjusted annual disease-specific cost of non-adherence per person ranged from $949 to $44,190, and the authors concluded that standardised adherence and cost measures are needed.
## Key findings
- The review included 79 individual studies across 14 disease groups; search strategies retrieved 2768 records, 289 were full-text reviewed, and 79 were included.
- Reported annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44,190 (2015 US$); costs attributed to “all causes” non-adherence ranged from $5271 to $52,341.
- Across studies reporting total or total healthcare costs, 39 studies (49%) found non-adherence costs were greater than adherence costs, while 11 studies (15%) found the opposite.
- The most-used adherence metric was medication possession ratio (MPR), reported in 51 studies (63%); the next most common was proportion of days covered (PDC) at 11%.
- Quality assessment found 10 high-quality, 59 medium-quality, and 10 low-quality studies; no full economic evaluation was conducted in any included study.
## Methods
- Design: Systematic review conducted according to PRISMA and registered in PROSPERO (CRD42015027338).
- Data/sample: Searches were run in PubMed and Scopus in September 2017, with no publication date or language restrictions; included studies had to report the monetary cost of medication non-adherence for any disease state and provide original data.
- Main analysis: Two reviewers appraised studies using a modified Drummond checklist; costs were converted to 2015 US$, extracted by outcome indicator, and the authors attempted but could not perform a meta-analysis because of heterogeneity and missing statistical parameters.
## Limitations
- The paper states that a meta-analysis could not be performed because of heterogeneity in study design and lack of required statistical parameters, particularly standard deviations.
- The authors note that differences in methodological strategies, adherence definitions, and cost indicators made comparison across studies difficult and limited estimation of the true magnitude of costs.
- Evident from the text: the evidence base was dominated by US studies (66 of 79; 83%), and many studies were partial economic evaluations rather than full economic evaluations, which limits generalisability and comparability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
4 Valid · 0 Not valid · 58 Not checked · 72 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“While Zhao et al80 categorised participants into adherence subgroups, finding that total healthcare costs were lower for the non-adherent population.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Supportedcites [80] Zhao, 2014, Associations between statin adherence level, health care costs, and utilization, J Manag Care Spec Pharm source
The Statistical Analysis section divides participants into statin-adherence groups. The results report that the lowest-adherence group (MPR <40%) had lower estimated total health care costs over one year than every higher-adherence group; the difference was statistically significant for all but the 70%–79% group. This supports the citing sentence’s comparison, although the paper uses a specific low-adherence group rather than a single category of all non-adherent patients. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One study measured the influence of medication non-adherence on direct healthcare costs in metabolic conditions, reporting an unadjusted attributable total cost of $138 525.54”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
The Methods and Results report an analysis of cinacalcet adherence and direct healthcare costs in dialysis patients with secondary hyperparathyroidism, including unadjusted 12-month costs. The Results refer to a table of mean costs, but the values are absent from our copy; no passage verifies the claimed $138,525 unadjusted attributable total cost. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The findings were that, for all levels of non-adherence, costs of non-adherence were higher for Medicare supplemental patients.45”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Partly supportedcites [45] Halpern, 2011, The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis, J Manag Care Pharm sourceExperimental — accuracy not yet measured
The medical-cost results (page unavailable) report higher adjusted costs with low versus high adherence in both groups, with a larger percentage increase in Medicare Advantage patients (18%) than commercial patients (12%). Moderate adherence was also associated with higher costs in the Medicare Advantage group, but not significantly in the commercial group. The claim calls these patients “Medicare supplemental” rather than Medicare Advantage and does not specify that the comparison concerns adjusted percentage increases, so its broader cost comparison is not established. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted total cost of non-adherence across all disease groups ranged from $949 to $52 341, while the unadjusted total cost ranged from $669 to $162 699.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Medication non-adherence and costs
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
67 more claims
Create a free account to see all 134 claims and every source verdict.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 28
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Medication non-adherence is a widespread problem that causes high costs worldwide [5–10].”
From Medication adherence influencing factors—an (updated) overview of systematic reviews (2019) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, a person-centered approach predicts better outcomes, such as fewer relapses, suicide and overall mortality [91].”
From Therapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis (2023) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“Only then will it be possible to contribute to the improvement of clinical and social outcomes, generate commitment, and guarantee a quality of services that translates into increased adherence rates and reduced number of hospitalizations and all associated costs (including pharmacy costs and inpatient and outpatient costs) [91].”
From Therapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis (2023) · cites this paper as [91]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729 · cited 4×
“The adjusted cost of medication non-adherence was reported in 14 studies with an estimated range of $5271–52 341.(10) 29 31 56 58–60 70 75 76 83 84 86 90 Sokol et al(10) reported the all-cause cost of non-adherence through subgroup analysis of disease states and MPR levels, while Pittman et al(60) reported only using…”
BackgroundMethodInfluentialInterventions for helping patients to follow prescriptions for medications
Haynes, R., McDonald, H., Garg, A., & Montague, P. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011 · Cited by 911
Hess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h018 · Cited by 756
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603 · cited 2×
“65 81 98 Six studies used adjusted costs, finding that the total annual cost of non-adherence per patient ranged from $3252 to $19 363.(23) 25 58 59 72 90 Bagalman et al(25) focused primarily on”
BackgroundResultIMS Institute for Healthcare Informatics
Evans, R. (2014) · Nursing Standard · doi:10.7748/ns2014.04.28.32.30.s36 · Cited by 594
Medication Adherence Leads To Lower Health Care Use And Costs Despite Increased Drug Spending
Roebuck, M. C., Liberman, J. N., Gemmill-Toyama, M., & Brennan, T. A. (2011) · Health Affairs · doi:10.1377/hlthaff.2009.1087 · Cited by 460 · cited 1×
“Justification of the associated financial benefit may incentivise health policy discussion about the value of medication adherence and promote the adoption of medication adherence intervention programmes.(15) The objective of this systematic review was, first, to determine the economic impact of medication non-adheren…”
BackgroundChronic Disease Prevention and Health Promotion
Schmidt, H. (2016) · Public Health Ethics Analysis · doi:10.1007/978-3-319-23847-0_5 · Cited by 441
A web-based tool for adjusting costs to a specific target currency and price year
Shemilt, I., James, T., & Marcello, M. (2010) · Evidence & Policy · doi:10.1332/174426410x482999 · Cited by 411 · cited 2×
“This online tool uses a two-stage computation process to adjust estimates of costs for currency and/or price year using a Gross Domestic Product deflator index and Purchasing Power Parities (PPP) for Gross Domestic Product.”
MethodHuybrechts, K. F., Ishak, K. J., & Caro, J. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.022 · Cited by 346
Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.6.805 · Cited by 281 · cited 3×
“Due to the advances in technology available to record and assess medication non-adherence, the inclusion of studies undertaken in the late 1990s and early 2000s may have affected the comparability of results, despite the fact that these studies met the inclusion criteria.(22) 23 64 72 73 97 The quality of data present…”
BackgroundResultInfluentialDarkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271 · cited 2×
“Two studies evaluated the effects of medication non-adherence in cancer.(33) 74 One study reported total annual costs of $119 416,(74) while the other gave a subgroup analysis based on classified adherence levels.”
BackgroundScientific, B. (2009) · Cited by 266
Pulmonary medication adherence and health-care use in cystic fibrosis
Quittner, A. L., Zhang, J., Marynchenko, M., Chopra, P. A., Signorovitch, J., Yushkina, Y., & Riekert, K. A. (2014) · Chest · doi:10.1378/chest.13-1926 · Cited by 250
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population
Davis, K. L., Candrilli, S. D., & Edin, H. M. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2007.01414.x · Cited by 241 · cited 1×
“All reported unadjusted costs using an MPR cut-off of <80%.(35) 41 42 The”
MethodFaught, R. E., Weiner, J. R., Guérin, A., Cunnington, M. C., & Duh, M. S. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01794.x · Cited by 226
Tan, H., Cai, Q., Agarwal, S., Stephenson, J. J., & Kamat, S. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0093-7 · Cited by 222
Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs
Dragomir, A., Côté, R., Roy, L., Blais, L., Lalonde, L., Bérard, A., & Perreault, S. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181d567bd · Cited by 221
Medication Nonadherence in Diabetes
Egede, L. E., Gebregziabher, M., Dismuke, C. E., Lynch, C. P., Axon, R. N., Zhao, Y., & Mauldin, P. D. (2012) · Diabetes Care · doi:10.2337/dc12-0572 · Cited by 195
Non-adherence to antipsychotic medication regimens: Associations with resource use and costs
Knapp, M., King, D., Pugner, K., & Lapuerta, P. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.6.509 · Cited by 191 · cited 1×
“In total, 44 studies (56%) reported unadjusted costs,(22) 26 27 30 32–36 38–42 45 47–49 51–55 57 62–67 71 74 80–82 85 87–89 91–93 98 21 (26%) adjusted costs,(10) 23–25 29 31 43 50 56 58–60 70 72 75–77 83 84 86 90 11 a combination of adjusted and unadjusted,(28) 37 44 46 61 68 69 73 78 79 96 2 unadjusted and predicted(…”
Karve, S., Cleves, M. A., Helm, M., Hudson, T. J., West, D. S., & Martin, B. C. (2008) · Medical Care · doi:10.1097/mlr.0b013e31817924d2 · Cited by 176
Jha, A. K., Aubert, R. E., Yao, J., Teagarden, J. R., & Epstein, R. S. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1198 · Cited by 174 · cited 3×
“Many studies have examined the relationship between non-adherence and economic outcomes using a cross-sectional analysis.(50) The implications of this are that potentially crucial confounders such as baseline status are ignored.”
BackgroundInfluentialRizzo, J. A., & Robert Simons, W. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80018-5 · Cited by 174 · cited 1×
“Unadjusted costs were measured in six studies with the annual total healthcare costs and/or total costs of non-adherence ranging from $1433 to $8377.(64) 66 80 92 94 95 Rizzo et al(64) reported cost findings through subgroup analysis of five conditions.”
BackgroundHydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease
Candrilli, S. D., O’Brien, S. H., Ware, R. E., Nahata, M. C., Seiber, E. E., & Balkrishnan, R. (2010) · American Journal of Hematology · doi:10.1002/ajh.21968 · Cited by 163
Antihypertensive medication adherence and subsequent healthcare utilization and costs.
Pittman, D. G., Tao, Z., Chen, W., & Stettin, G. (2010) · PubMed · Cited by 159
Hong, J., Reed, C. C., Novick, D., Haro, J. M., & Aguado, J. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.04.016 · Cited by 151 · cited 2×
“%) were conducted in the USA, 10 22–85 four in Europe, 86–89 four in Asia, 90–93 three in Canada, 94–96 one in the UK 97 and one across multiple countries throughout Europe and the UK.”
BackgroundPrevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy
Ettinger, A. B., Manjunath, R., Candrilli, S. D., & Davis, K. L. (2008) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.10.021 · Cited by 146
Sattler, E. L. P., Lee, J. S., & Perri, M. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0074-z · Cited by 127 · cited 1×
“These percentages were consistent with those found recently by Sattler et al.(102) Even though the measures of medication non-adherence may be comparable, the definition of MPR and the cut-off points to define non-adherence differed significantly.”
ResultWu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903396469 · Cited by 126
Adherence to Statins, Subsequent Healthcare Costs, and Cardiovascular Hospitalizations
Pittman, D. G., Chen, W., Bowlin, S. J., & Foody, J. M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.052 · Cited by 123
Ivanova, J. I., Bergman, R., Birnbaum, H. G., Phillips, A. L., Stewart, M., & Meletiche, D. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.667027 · Cited by 115
Eaddy, M. T., Grogg, A. L., & Locklear, J. C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.02.003 · Cited by 113
The COMET Initiative database: progress and activities from 2011 to 2013
Gargon, E., Williamson, P. R., Altman, D. G., Blazeby, J. M., & Clarke, M. J. (2014) · Trials · doi:10.1186/1745-6215-15-279 · Cited by 108 · cited 1×
“The core outcome set must take into consideration the perspective of the intended audience and the proportion of non-adherence cost that is attributable to each outcome to determine an appropriate model.(104) The critical indicators based on the findings of this review include total costs, pharmacy costs, inpatient co…”
BackgroundCasciano, J. P., Dotiwala, Z., Martin, B. C., & Kwong, W. J. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.4.302 · Cited by 107 · cited 2×
“assessed in all of the studies with the major indicators measured including pharmacy costs,(10) 31 60 61 75 medical costs(10) 24 31 60 75 and outpatient costs.(31) 61 The annual”
BackgroundHong, J. S., & Kang, H. C. (2011) · Medical Care · doi:10.1097/mlr.0b013e31820292d1 · Cited by 104
Kane, S. V., Chao, J., & Mulani, P. M. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0069-7 · Cited by 100
Davis, K. L., Edin, H. M., & Allen, J. K. (2010) · Movement Disorders · doi:10.1002/mds.22999 · Cited by 99 · cited 1×
“The unadjusted total cost ranged from $10 988 to $52 023.(34) 37 71 Wei et al(71) further subgrouped patients into MPR adherence percentage categories and found that costs increased in all economic indicators (inpatient costs and outpatient costs) as adherence decreased, except for pharmacy costs which decreased with…”
BackgroundHalpern, R., Iqbal, S. U., Kazis, L. E., Macarios, D., & Badamgarav, E. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.1.25 · Cited by 94 · cited 1×
“non-adherence were higher for Medicare supplemental patients.(45)”
Tkacz, J. P., Volpicelli, J. R., Un, H., & Ruetsch, C. R. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.10.014 · Cited by 88
Robinson, R. L., Long, S. R., Chang, S., Able, S. L., Başer, O., Obenchain, R. L., & Swindle, R. W. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.1.43 · Cited by 83
(2011) · PubMed · Cited by 80
Consequences of poor compliance with bisphosphonates
Briesacher, B. A., Andrade, S. E., Yood, R. A., & Kahler, K. H. (2007) · Bone · doi:10.1016/j.bone.2007.07.009 · Cited by 75 · cited 1×
“87 Also, 4 out of 11 studies reported the adjusted cost of medication non-adherence in addition to reporting unadjusted costs.(28) 78 79 86 Three studies further classified non-adherence through subgroup analysis, with Briesacher et al(28) using MPR 20% interval increases and the two studies conducted by Zhao et al(78…”
ResultOfford, S. J., Lin, J., Mirski, D. F., & Wong, B. J. O. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0016-5 · Cited by 73
Accounting for Noncompliance in Pharmacoeconomic Evaluations
Hughes, D. A., Bagust, A., Haycox, A. R., & Walley, T. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119120-00001 · Cited by 73
New Math on Drug Cost-Effectiveness
Bach, P. B. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1512750 · Cited by 71 · cited 1×
“Healthcare reformers and payers have repeatedly relied on cost-effectiveness analysis to help healthcare systems deal with the rising costs of care.(14) However, there is still a budgetary problem that needs to be considered, especially given the widespread policy debate over how to best bend the healthcare cost curve…”
BackgroundDragomir, A., Côté, R., White, M., Lalonde, L., Blais, L., Bérard, A., & Perreault, S. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00583.x · Cited by 69 · cited 1×
“The remaining studies used five key indicators to determine the economic impact: inpatient costs,(66) 92 outpatient costs,(66) 92 pharmacy costs,(66) 94 95 medical costs(94) 95 and hospitalisation costs.(94) 95”
Hansen, R. A., Farley, J. F., Droege, M., & Maciejewski, M. L. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.07.011 · Cited by 68
Delea, T. E., Stanford, R. H., Hagiwara, M., et al. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802557344 · Cited by 60 · cited 1×
“medication non-adherence, with significant variation in the method of adherence classification.(36) 38 52 63 88 Two studies used MPR,(36) 63 one the Morisky four-item scale,(52)”
Method(2010) · PubMed · Cited by 58
Jiang, Y., & Ni, W. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1634 · Cited by 56 · cited 1×
“ence ranged from $2512 to $25 920 as reported in four studies.(51) 65 81 98 Becker et al(27) used a subgroup analysis to”
MethodStroupe, K. T., Teal, E. Y., Tu, W., Weiner, M., & Murray, M. D. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.779 · Cited by 52
Mitra, D., Hodgkins, P., Yen, L., Davis, K. L., & Cohen, R. D. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-132 · Cited by 51
Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy
Modi, A., Siris, E. S., Tang, J., & Sen, S. S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1016605 · Cited by 48
Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs
Carter, C. T., Waters, H. C., & Smith, D. B. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0048-7 · Cited by 48 · cited 1×
“non-adherence with neither reporting the total cost nor total healthcare costs.(30) 53 Carter et al(30) reported hospitalisation costs to be $42 854 while Kane et al(53) reported”
BackgroundGosselin, A., Luo, R. T., Lohoues, H., Toy, E. L., Lewis, B., Crawley, J. A., & Duh, M. S. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00399.x · Cited by 43 · cited 1×
“of medication non-adherence per patient using the MPR method.(43) 56 70 Of these, two reported the total cost ($12 085 and $37 151)(43) 70 with the main contributors”
MethodMedication adherence and improved outcomes among patients with type 2 diabetes.
Curtis, S. E., Boye, K. S., Lage, M. J., & García‐Pérez, L. (2017) · PubMed · Cited by 41
Sunyecz, J. A., Mucha, L., Başer, O., Barr, C. E., & Amonkar, M. M. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0586-2 · Cited by 40
Cooke, C. E., Lee, H. Y., & Xing, S. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.1.86 · Cited by 40
Joshi, A. V., Madhavan, S. S., Ambegaonkar, A. J., Smith, M. J., Scott, V., & Dedhia, H. V. (2006) · Journal of Asthma · doi:10.1080/02770900600857010 · Cited by 40
Becker, M. A., Young, M. S., Ochshorn, E., & Diamond, R. J. (2007) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-006-0108-5 · Cited by 39 · cited 2×
“and 10 of low quality.(27) 48 59 64 67 73 82 89 91 Scores ranged from 26.”
BackgroundMiravitlles, M., Sicras, A., Crespo, C., Cuesta, M., Brosa, M., Galera, J., Lahoz, R., Lleonart, M., & Riera, M. I. (2013) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465813484080 · Cited by 39
Wu, J., Seiber, E. E., Lacombe, V. A., Nahata, M. C., & Balkrishnan, R. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p539 · Cited by 37 · cited 1×
“50 73 75 83 96 One study reported total costs in relation to subgroup analysis based on MPR level,(73) and another reported total healthcare costs through subgroup analysis of commercially insured and Medicare supplemental patients.(75) Curtis et al(83) used a diabetic population to report all-cause costs, with non-ad…”
BackgroundWei, Y. J., Palumbo, F. B., Simoni, J. M., Shulman, L. M., Stuart, B., Beardsley, R. S., & Brown, C. H. (2014) · Value in Health · doi:10.1016/j.jval.2013.12.003 · Cited by 36
Davis, J. R., Wu, B., Kern, D. M., Tunceli, O., Fox, K. M., Horton, J., Legg, R. F., & Trudo, F. J. (2017) · Europe PMC (PubMed Central) · Cited by 34
Offord, S. J., Lin, J., Wong, B. J. O., Mirski, D. F., & Baker, R. A. (2013) · Community Mental Health Journal · doi:10.1007/s10597-013-9638-y · Cited by 33
Wan, G. J., Kozma, C. M., Slaton, T. L., Olson, W. H., & Feagan, B. G. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.909436 · Cited by 33 · cited 1×
“Only one study identified the form of economic evaluation used and justified it in relation to the questions that were being addressed.(70) The item ‘the choice of discount rate is stated and justified’ was applicable only to studies covering a time period of >1 year; all studies that cover >1 year failed to identify…”
BackgroundAssociation of cinacalcet adherence and costs in patients on dialysis
Lee, A., Song, X., Khan, I., Belozeroff, V., Goodman, W., Fulcher, N., & Diakun, D. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.627404 · Cited by 33 · cited 1×
“One study measured the influence of medication non-adherence on direct healthcare costs in metabolic conditions, reporting an unadjusted attributable total cost of $138 525.(54) The economic indicators used to derive this cost were inpatient costs ($16 192), outpatient costs ($111 100), emergency department visit cost…”
BackgroundOlsen, K. R., Hansen, C. A., & Abrahamsen, B. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2365-y · Cited by 32
Indirect costs associated with nonadherence to treatment for bipolar disorder
Bagalman, E., Yu-Isenberg, K. S., Durden, E., Crivera, C., Dirani, R., & Bunn, W. B. (2010) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0b013e3181db811d · Cited by 32
Joe, S., & Lee, J. S. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1156-3 · Cited by 32
Economic Impact of Patient Adherence with Antidepressant Therapy Within a Managed Care Organization
White, T., Vanderplas, A. M., Ory, C., Dezii, C. M., & Chang, E. Y. (2003) · Disease Management & Health Outcomes · doi:10.2165/00115677-200311120-00006 · Cited by 30
Delea, T. E., Thomas, S. K., & Hagiwara, M. (2011) · CNS Drugs · doi:10.2165/11538970-000000000-00000 · Cited by 28
Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes.
Ruetsch, C. R., Tkacz, J. P., Nadipelli, V. R., Brady, B. L., Ronquest, N. A., Un, H., & Volpicelli, J. R. (2017) · PubMed · Cited by 28
Determinants of the Cost of Health Services Used by Veterans With HIV
Barnett, P. G., Chow, A., Joyce, V. R., Bayoumi, A. M., Griffin, S. C., Nosyk, B., Holodniy, M., Brown, S. T., Sculpher, M., Anis, A. H., et al. (2011) · Medical Care · doi:10.1097/mlr.0b013e31821b34c0 · Cited by 27
White, T., Vanderplas, A. M., Chang, E. Y., Dezii, C. M., & Abrams, G. D. (2004) · Disease Management & Health Outcomes · doi:10.2165/00115677-200412030-00004 · Cited by 26
Dilokthornsakul, P., Chaiyakunapruk, N., Nimpitakpong, P., et al. (2012) · Value in Health · doi:10.1016/j.jval.2011.11.019 · Cited by 26
Cost and Consequences of Noncompliance to Oral Bisphosphonate Treatment
Eisenberg, D. F., Placzek, H., Gu, T., Krishna, A., & Tulsi, B. B. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.1.56 · Cited by 26
Gentil, L., Vasiliadis, H., Préville, M., & Berbiche, D. (2015) · PubMed Central · doi:10.5888/pcd12.150412 · Cited by 24
Associations Between Statin Adherence Level, Health Care Costs, and Utilization
Zhao, Y., Zabriski, S., & Bertram, C. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.7.703 · Cited by 23
Medication Adherence and Healthcare Costs among Fibromyalgia Patients Treated with Duloxetine
Zhao, Y., Chen, S., Wu, N., Fraser, K. A., & Boulanger, L. (2010) · Pain Practice · doi:10.1111/j.1533-2500.2010.00431.x · Cited by 21 · cited 1×
“commercial and Medicare supplemental patient populations.(77) Zhao et al(77) reported the adjusted annual cost in the commercial population to be $22 609, and in the Medicare supplemental group, $28 126.”
BackgroundRobertson, A. G., Swanson, J. W., Van Dorn, R. A., & Swartz, M. S. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201400247 · Cited by 21
Wu, N., Chen, S., Boulanger, L., Fraser, K. A., Bledsoe, S., & Zhao, Y. (2009) · Journal of Medical Economics · doi:10.3111/13696990903240559 · Cited by 18
Medication non-adherence as a cause of hospital admissions.
Payero, M. Á., de Castro, N. M. L., Samartín, M. U., Vila, A. M., Vázquez, C., & Corrales, G. P. (2014) · PubMed · doi:10.7399/fh.2014.38.4.7660 · Cited by 18
Hazel-Fernandez, L. A., Louder, A. M., Foster, S. A., Uribe, C. L., & Burge, R. T. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-4 · Cited by 16 · cited 2×
“PDC <50%, the cost of this category ranged from $16 938 to $43 404.(47) 78 79”
BackgroundBuysman, E. K., Anderson, A. J., Bacchus, S., & Ingham, M. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0500-4 · Cited by 15
Hagen, S. E., Wright, D. W., Finch, R., Talamonti, W. J., & Edington, D. W. (2013) · Population Health Management · doi:10.1089/pop.2013.0009 · Cited by 14 · cited 2×
“A further four studies reported unadjusted cost findings(13) 82 91 93 with an additional four studies reporting unadjusted costs in combination with adjusted values.(44) 46 73 96 Unadjusted total healthcare costs and/ or total costs ranged from $1142 to $7951.”
BackgroundResultAn, S.-Y., Kim, H. J., Chun, K. H., Kim, T. H., Jeon, J. Y., Kim, D. J., Han, S. J., Kim, Y. S., Woo, J., Ahn, K. J., et al. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.012 · Cited by 14
Diehl, J. L., Daw, J. R., Coley, K. C., et al. (2010) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2010.16.1.23 · Cited by 14 · cited 1×
“one the Global Initiative for Chronic Obstructive Lung Disease 2007 guidelines(88) and one a 37-day gap in claims data.(38) Joshi et al(52) reported on the indirect costs of medi-”
BackgroundHealthcare Costs Associated with Antiretroviral Adherence Among Medicaid Patients
Pruitt, Z., Robst, J., Langland-Orban, B., & Brooks, R. G. (2015) · Applied Health Economics and Health Policy · doi:10.1007/s40258-014-0138-1 · Cited by 11 · cited 1×
“The total cost of non-adherence in AIDS was $30 523.(62) All studies used comparable indicators (total cost, inpatient cost, outpatient cost, pharmacy cost) to determine the cost of non-adherence.”
BackgroundKjellberg, J., Jorgensen, A. D., Vestergaard, P., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3683-7 · Cited by 11
Vermeire, E., Avonts, D., Royen, P. V., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05153-9 · Cited by 7
Zhao, Y., Johnston, S. S., Smith, D. M., McMorrow, D., Krege, J. H., & Krohn, K. (2013) · Bone · doi:10.1016/j.bone.2013.12.016 · Cited by 5 · cited 1×
“26 36 43 58 62 65 80 91 93 94 Four reported fluctuating findings based on varying non-adherence cost subcategories,(33) 47 66 92 and two studies reported conflicting findings between adjusted and unadjusted costs.(78) 79 Higher all-cause total non-adherence costs and lower disease group-specific non-adherence costs we…”
ResultZhao, Y. W., Johnston, S. S., Smith, D. M., McMorrow, D., Krohn, K., & Krege, J. H. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2324-7 · Cited by 4
Cited by
SCOPE 2021: a new scorecard for osteoporosis in Europe
Kanis, J. A., Norton, N., Harvey, N. C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E. V., Willers, C., & Borgström, F. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-020-00871-9 · Cited by 714
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Medication adherence influencing factors—an (updated) overview of systematic reviews
Gast, A., & Mathes, T. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1014-8 · Cited by 560
Kvarnström, K., Westerholm, A., Airaksinen, M., & Liira, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071100 · Cited by 470
Walsh, C. A., Cahir, C., Tecklenborg, S., Byrne, C., Culbertson, M. A., & Bennett, K. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14075 · Cited by 269
“A recent review on the economic burden of medication non‐adherence cited the wide variability in adherence measurement and study methodologies as a barrier to meta‐analysis.(114) This is evident in the current review.”
Background
Metadata
- Authors
- Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V.
- Affiliations
- University of Technology Sydney (AU)
- Department of Social Pharmacy Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), University of Lisbon, Lisbon, Portugal
- The University of Sydney (AU)
- Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia
- Corresponding author
- Cutler, Rachelle Louise
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2018-01
- Volume
- 8
- Issue
- 1
- Pages
- e016982
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5780689
- OpenAlex
- W2790318238
- Cited by
- 900
- References
- 113
- Citations by year
- 2026: 83 · 2025: 111 · 2024: 159 · 2023: 134 · 2022: 112 · 2021: 124 · 2020: 91 · 2019: 68 · 2018: 16
- FWCI
- 16.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OPUS - Open Publications of UTS Scholars (University of Technology Sydney) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Australian Government
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- medication non-adherence, economic burden, health care costs, medication possession ratio, adherence measurement, health policy
- MeSH terms
- Cost-Benefit Analysis, Disease, Drug Therapy, Humans, Drug Monitoring, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.